{"id":6064,"date":"2021-06-08T14:40:34","date_gmt":"2021-06-08T13:40:34","guid":{"rendered":"https:\/\/touchrespiratory.com\/?post_type=media_gallery&p=6064"},"modified":"2021-06-08T14:40:34","modified_gmt":"2021-06-08T13:40:34","slug":"douglas-mapel-ats-2021-the-rate-of-ed-visits-in-patients-with-copd-in-the-impact-trial","status":"publish","type":"media_gallery","link":"https:\/\/touchrespiratory.com\/copd\/conference-hub\/douglas-mapel-ats-2021-the-rate-of-ed-visits-in-patients-with-copd-in-the-impact-trial\/","title":{"rendered":"Douglas Mapel, ATS 2021: The Rate of ED Visits in Patients with COPD in the IMPACT Trial"},"content":{"rendered":"

It was a pleasure to meet with Dr Douglas Mapel<\/strong> (Northern Arizona Pulmonary Associates – Critical Care, Flagstaff, AZ, US) <\/span>to talk around his abstract on ‘Reduction in Emergency Department (ED) Visits in Patients with Chronic Obstructive Pulmonary Disease (COPD): Analysis of the IMPACT Trial.<\/em>‘, which was presented at ATS 2021 International Conference, 14-19 May, 2021.<\/p>\n

Questions<\/strong><\/p>\n

    \n
  1. How substantial a health burden are emergency department (ED) visits associated with COPD? (0:25)<\/li>\n
  2. What did the IMPACT trial teach us about the efficacy and safety of single inhaler fluticasone furoate\/umeclidinium\/vilanterol (FF\/UMEC\/VI)? (0:47)<\/li>\n
  3. What were the findings of the analysis of the annual rate of ED visits in the IMPACT trial? (1:51)<\/li>\n
  4. What is the clinical significance of these findings? (2:30)<\/li>\n
  5. How can we further refine the role of inhaled corticosteroids in COPD patients? (3:12)<\/li>\n<\/ol>\n

    Disclosures:<\/strong> Douglas Mapel\u00a0has nothing to disclose in relation to this video.<\/p>\n

    Support:<\/strong>\u00a0Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.<\/p>\n

    Filmed as a highlight of ATS 2021 (Virtual).<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"

    It was a pleasure to meet with Dr Douglas Mapel (Northern Arizona Pulmonary Associates – Critical Care, Flagstaff, AZ, US) to talk around his abstract on ‘Reduction in Emergency Department (ED) Visits in Patients with Chronic Obstructive Pulmonary Disease (COPD): Analysis of the IMPACT Trial.‘, which was presented at ATS 2021 International Conference, 14-19 May, […]<\/p>\n","protected":false},"featured_media":6065,"template":"","class_list":["post-6064","media_gallery","type-media_gallery","status-publish","has-post-thumbnail","hentry","vocabulary_1-copd","video_categories-ats-highlights"],"acf":[],"_links":{"self":[{"href":"https:\/\/touchrespiratory.com\/wp-json\/wp\/v2\/media_gallery\/6064","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/touchrespiratory.com\/wp-json\/wp\/v2\/media_gallery"}],"about":[{"href":"https:\/\/touchrespiratory.com\/wp-json\/wp\/v2\/types\/media_gallery"}],"version-history":[{"count":2,"href":"https:\/\/touchrespiratory.com\/wp-json\/wp\/v2\/media_gallery\/6064\/revisions"}],"predecessor-version":[{"id":6067,"href":"https:\/\/touchrespiratory.com\/wp-json\/wp\/v2\/media_gallery\/6064\/revisions\/6067"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/touchrespiratory.com\/wp-json\/wp\/v2\/media\/6065"}],"wp:attachment":[{"href":"https:\/\/touchrespiratory.com\/wp-json\/wp\/v2\/media?parent=6064"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}